Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a...
Month: May 2022
Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and...
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical...
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
Fremont, CA, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it...
Quotient Limited to Host Key Opinion Leader Webinar on its MosaiQ™ Solution
Virtual event on Monday, May 23rd at 11:00 AM ETThe webinar will provide a detailed discussion on the current landscape...
Accelus Receives U.S. FDA 510(k) Clearance for its FlareHawk TiHawk11 Interbody Fusion System
TiHawk11 Interbody Fusion System Accelus recently received U.S. FDA 510(k) Clearance for its TiHawk11, the latest addition to its FlareHawk...
Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the...
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its...
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma...
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choiceATLANTA, May 12,...
Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail,...
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating...
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology,...
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for...
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic...
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
Data showed OK-432 was clinically successful in treating lymphatic malformations and support a favorable safety profileNEW YORK, May 12, 2022...
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20...
Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company...
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Cash position bolstered through debt financing to support operations into the fourth quarter of 2023NEEDHAM, Mass., May 12, 2022 (GLOBE...
